| Datum | Källa | Rubrik | Typ | Alternativ |
|---|---|---|---|---|
| 2024-04-25 | Enzymatica | Enzymatica AB: Delårsrapport Q1/2024: MDR-certifieringen öppnar stora kommersiella möjligheter | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-25 | Enzymatica | Enzymatica AB: Interim report Q1/2024: MDR certification opens up great commercial opportunities | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-09 | Enzymatica | Enzymatica AB: Enzymatica publicerar årsredovisning för 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-09 | Enzymatica | Enzymatica AB: Enzymatica publishes annual report for 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-27 | Enzymatica | Notice of Annual General Meeting 2024 in Enzymatica AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-27 | Enzymatica | Kallelse till årsstämma 2024 i Enzymatica AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-20 | Enzymatica | Enzymatica AB: BioStock: Enzymatica kommenterar MDR-certifieringen för ColdZyme | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-20 | Enzymatica | Enzymatica AB: BioStock: Enzymatica comments on MDR certification for ColdZyme | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-14 | Enzymatica | Enzymatica AB: Enzymatica offentliggör utfall i företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-14 | Enzymatica | Enzymatica AB: Enzymatica announces outcome of new rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-11 | Enzymatica | Enzymatica AB: Enzymaticas munspray ColdZyme® erhåller CE-certifiering enligt nya EU-förordningen MDR | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-11 | Enzymatica | Enzymatica AB: ColdZyme® certified under the new EU medical device regulation (MDR) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-04 | Enzymatica | Enzymatica AB: BioStock: Enzymatica förbereder för expansion genom emission | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-02-26 | Enzymatica | Enzymatica AB: BioStock: Enzymatica's partners await MDR certification and study results | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-02-26 | Enzymatica | Enzymatica AB: BioStock: Enzymaticas partners inväntar MDR-certifiering och studieresultat | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-02-20 | Penser Access by Carnegie | Penser Access by Carnegie: Enzymatica - Lägger ännu ett tufft år bakom sig | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-02-19 | Enzymatica | Enzymatica AB: Enzymatica publishes information memorandum about rights issue of shares | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-19 | Enzymatica | Enzymatica AB: Enzymatica offentliggör informationsmemorandum med anledning av företrädesemission av aktier | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-19 | Redeye | Redeye: Enzymatica Q4 - Important year ahead and an expected rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-16 | Enzymatica | Enzymatica AB: Enzymatica's rights issue is secured to 100 percent | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-16 | Enzymatica | Enzymatica AB: Enzymaticas nyemission är säkerställd till 100 procent | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-16 | Enzymatica | Enzymatica AB: Year-end report 2023: Scientific and regulatory progress generating international interest | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-16 | Enzymatica | Enzymatica AB: Bokslutskommuniké 2023: Vetenskapliga och regulatoriska framsteg skapar internationellt intresse | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-16 | Enzymatica | Enzymatica AB: Styrelsen i Enzymatica beslutar om nyemission om 27,4 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-16 | Enzymatica | Enzymatica AB: Enzymatica's Board of Directors decides on a new rights issue of SEK 27.4 million | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-12-21 | Enzymatica | Enzymatica AB: Enzymatica's Chairman to BioStock: "Our new research data makes 2024 an exciting year" | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-12-21 | Enzymatica | Enzymatica AB: Enzymaticas ordförande till BioStock: "Våra nya forskningsdata gör 2024 till ett spännande år" | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-30 | Enzymatica | Enzymatica AB: Enzymatica byter Certified Adviser till Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-30 | Enzymatica | Enzymatica AB: Enzymatica changes Certified Adviser to Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-08 | Penser Access | Penser Access: Fortsatt svaga försäljningssiffror - Enzymatica | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-08 | Enzymatica | Enzymatica AB: BioStock: Enzymatica arbetar för att stärka distributörsledet | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-08 | Enzymatica | Enzymatica AB: BioStock: Enzymatica focuses on strengthening the distributor level | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-08 | Redeye | Redeye: Enzymatica Q3 - The STADA partnership creating concerns about the future | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-07 | Enzymatica | Enzymatica AB: Kvartalsrapport Q3/2023: Forskningsresultat som förändrar spelplanen | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-07 | Enzymatica | Enzymatica AB: Interim report Q3/2023: Research results that reshape the competitive landscape | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2023-09-22 | Enzymatica | Enzymatica AB: BioStock: Enzymaticas ColdZyme minskar mängden rhinovirus och halsont | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-09-21 | Enzymatica | Enzymatica AB: Delrapport från klinisk studie: ColdZyme minskar signifikant mängden rhinovirus samt symptom på halsont | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-09-21 | Enzymatica | Enzymatica AB: Interim report from clinical study: ColdZyme significantly reduces rhinovirus viral load and symptoms of sore throat | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-24 | Enzymatica | Enzymatica AB: BioStock: Enzymatica's CEO comments on promising in-vitro data for ColdZyme | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-08-24 | Enzymatica | Enzymatica AB: BioStock: Enzymaticas vd kommenterar lovande in-vitro data för ColdZyme | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-08-22 | Enzymatica | Enzymatica AB: Ny studie: ColdZyme bryter infektionscykeln och minskar mängden influensavirus signifikant | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-22 | Enzymatica | Enzymatica AB: New study: ColdZyme breaks viral infection cycle - significantly reducing influenza viral load | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-07-19 | Redeye | Redeye: Enzymatica Q2 2023 - Waiting for the cold season | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-07-18 | Penser Access | Penser Access: Kommande studieresultat i fokus - Enzymatica | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-07-18 | Enzymatica | Enzymatica AB: Interim report Q2/2023: An exciting and important time ahead | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2023-07-18 | Enzymatica | Enzymatica AB: Kvartalsrapport Q2/2023: En spännande och viktig tid framöver | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2023-05-16 | Penser Access | Penser Access: Interview with Enzymatica - Erik Penser Bank - May 16th 2023 | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-05-04 | Enzymatica | Kommuniké från årsstämma i Enzymatica AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-05-04 | Enzymatica | Bulletin from Annual General Meeting of Enzymatica AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-04-28 | Penser Access | Penser Access: Upp till bevis - Enzymatica | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-04-28 | Redeye | Redeye: Enzymatica Q1 2023 - A step in the right direction | Pressreleaser | Ladda ner | Visa Stäng |
|
Pressreleaser |
Redeye: Enzymatica Q1 2023 – A step in the right directionRedeye provides an update in relation to Enzymatica’s Q1 2023 report. Even if the report was a bit under our expectations, we are positive that the negative effects of the pandemic seem to disappear gradually. The sales during the quarter were SEK13.0m (SEK4.2m), a bit lower than our sales estimate of SEK16.2m, and EBIT came in at SEK-14.4m (SEK-18.1m) compared to our EBIT estimate of SEK-9.7m. We have only made minor changes in our sales and OPEX estimates for 2023. The changes do not render a difference in our valuation; therefore, we reiterate our base case of SEK6.5. Read more and download the Research Update. Follow companies at Redeye to receive the latest equity research within Life Science and Technology. This is a press release from Redeye – Research Powered Investment Banking. www.redeye.se/ |
||||
| 2023-04-27 | Enzymatica | Enzymatica AB: Interim report Q1/2023: Strong start to the year - Enzymatica's growth journey continues according to plan | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2023-04-27 | Enzymatica | Enzymatica AB: Kvartalsrapport Q1/2023: Stark start på året - Enzymaticas tillväxtresa fortsätter enligt plan | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
Kommande händelser
